Develop targeted radiopharmaceutical therapies for cancer treatment. Utilize a miniprotein radioconjugate platform to deliver radioisotopes to tumors. Now — the numbers.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.

This company is not turning a profit, so the market is pricing its sales instead: 191.5× for every dollar of annual revenue.

Against companies in its own sector, it looks cheaper than 48% of them.

Analysts' average target sits 61% above today's price.

We compared this company with its own sector across five subjects.

A score of 50 means class average.

Clearly below the class average.

Debt is low and cash is strong; the finances stand solid.

Clearly below the class average.

Clearly below the class average.

Clearly above the class average — a step short of the very top.

Growth: Sales growth trails the sector average.

Business Quality: Profit power and business quality trail similar companies in the sector.

On our five-subject report card, AKTS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: AKTS is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

Analysts’ average target sits above today’s price, yet the valuation grade (48/100) says the stock isn’t cheap.

Not covered, because the filings we hold do not carry it: the revenue breakdown, the price history.